A Critical Review of the Impact of Sarcoma on Psychosocial Wellbeing

Table 3

Participant characteristics.

First author	Participants (response %)^1	Type of sarcoma	Site	Age at study (years)	Gender male (%)
Sugarbaker et al. [94]	21 (91)	STS	Extremity	ns	ns
Weddington et al. [102]	33 (67)	BT, STS	Extremity	Range 15–71	45
Postma et al. [80]	33 (92)	BT	LL	Range 13–56	55
Rougraff et al. [86]	29 (13)	OS	LL	ns	66
Sammallahti et al. [88]	16 (100)	OS	All	Range 21–31	50
Christ et al. [36]	45 (69)	BT	LL	Range 17–34	58
Felder-Puig et al. [46]	60 (55)	BT	Extremity	M 23.5 (sd 4.3)	57
Davis et al. [41]	12 (92)	BT, STS	LL	M 34.4 (sd 11.6)	67
Hillmann et al. [56]	65 (97)	BT	LL	Range 11–24^3	62
Davis et al. [40]	172 (76)	STS	LL	M 51 (sd 15.2)	51
Veenstra et al. [101]	33 (97)	BT	LL	Range 16–50	55
Eiser et al. [44]	37 (93)	BT	LL	Range 12–47	57
Malo et al. [64]	53 (95)	BT	LL	M 36.7 (sd 18.3)	53
Rodl et al. [85]	22^2	BT	LL	Range 18–49	ns
Servaes et al. [90]	170 (75)	BT, STS	ns	Range 18–65	53
Marchese et al. [65]	18 (64)	OS	LL	Range 10–27	44
Nagarajan et al. [69]	528 (84)	BT	LL/pelvis	M 34.8 (sd 19.5)	49
Zahlten-Hinguranage et al. [107]	124 (66)	BT	LL	Range 14–76	63
Koopman et al. [61]	18 (90)	BT	Extremity	Range 12–23	72
Tabone et al. [96]	37^2	BT	All	Range 10–18	68
Gerber et al. [51]	32 (40)	BT	ns	M 35.4 (sd 10.6)	53
Hoffmann et al. [59]	45 (71)	BT	Pelvis	Range 16.1–83.2	64
Hopyan et al. [60]	45 (83)	BT	LL	Range 10–39	49
Marchese et al. [66]	68^2	BT	LL	Range 10–26	56
Schreiber et al. [89]	100 (90)	STS	Extremity	Range 18–86	56
Thijssens et al. [99]	39 (95)	STS	Extremity	Range 15–78	41
Wiener et al. [104]	34 (41)	BT, STS	ns	M 17 (sd 5)	53
Akahane et al. [28]	21 (72)	OS	LL	Range 8–69	81
Aksnes et al. [29]	57 (76)	BT	Extremity	Male M 34 (sd 9.4), female M 27 (sd 4.8)	54
Ginsberg et al. [52]	91^2	BT	LL	M 20.1 (sd 5.7)	53
Beck et al. [32]	97 (94)	BT	Pelvis/femur	IQR 33.3–66.5^3	68
Davidge et al. [38]	157 (100)	STS	Extremity	Range 16.1–87	62
Hinds et al. [57]	39 (93)	OS	All	Range 13–23	54
Hinds et al. [58]	66 (93)	OS	All	Range 5–23.5	55
Nagarajan et al. [70]	528 (84)	BT	LL	M 34.8 (sd 5.8)	49
Yonemoto et al. [106]	30 (55)	OS	All	Range 7–17^3	37
Barrera et al. [30]	28 (39)	BT	LL	M 25.1 (sd 4.5)	50
Bekkering et al. [34]	81 (92)	BT	Knee	M 16.9 (sd 4.2)	49
Robert et al. [84]	57 (57)	OS	Extremity	Range 16.1–52	35
Granda-Cameron et al. [54]	11 (65)	BT, STS	ns	M 44.5 (sd 13.7)	36
Nagarajan et al. [71]	733 (68)	OS	All	Range 13–51	52
Paredes et al. [74]	36 (88)	BT, STS	All	Range 18–72	53
Paredes et al. [73]	142^2	BT, STS	All	M 48.3 (sd 16.4)^4, M 48.1 (sd 17.7), M 48.3 (sd 18.5)	56
Expósito Tirado et al. [45]	17 (44)	OS, ES	Extremity	Range 20–25	41
Barrera et al. [31]	28 (40)	BT	LL	M 25.1 (sd 4.5)	50
Bekkering et al. [33]	44 (90)	BT	Knee	M 14.9 (sd 4.8)^3	61
Forni et al. [49]	20 (67)	BT	Femur	Range 17–38	60
Han et al. [55]	120 (100)	BT	LL	M 14.1 (sd 4.6)^3	66
Paredes et al. [76]	151^2	BT, STS	All	M 47.5 (sd 17)^4, M 44.9 (sd 16.9), M 46.9 (sd 18.1)	56
Paredes et al. [75]	36 (88)	BT, STS	All	M 40.5 (sd 16)	53
Reichardt et al. [82]	116^2	BT, STS	All	Range 18.5–83.4	41
Smorti [92]	32 (80)	BT	ns	Range 11–20	56
Sun et al. [95]	344 (97)	BT	LL	M 18.7 (sd 4.9)	57
Teall et al. [98]	28 (40)	BT	LL	Range 18–32	50
Marina et al. [67]	1094^2	BT, STS	Extremity	Range 10–53	Unclear
Mason et al. [68]	82 (82)	BT	LL	14–19.9	52
Liu et al. [63]	94 (88)	BT	LL	M 22.8 (sd 9.7)	45
Ostacoli et al. [72]	56^2	STS	All	M 53.5 (sd 14.1)	50
van Riel et al. [100]	10^2	BT	All	Range 12–17	60
Chan et al. [35]	79 (98)	BT, STS, GIST	ns	M 57.3 (sd 15.2)	58
Custers et al. [37]	54 (63)	GIST	GI	Range 21–84	54
Furtado et al. [50]	100 (40)	BT, STS	LL	Range 9–91	60
Gradl et al. [53]	12 (86)	BT	LL	M 33 (sd 11)	58
Rivard et al. [83]	45 (87)	STS	All	Range 24–83	78
Shchelkova and Usmanova [91]	82^2	BT	ns	Range 18–67	57
Stish et al. [93]	74 (56)	ES	All	Range 12.2–83.8	62
Tang et al. [97]	76 (75)	BT, STS	Extremity	Range 16–86	59
Fidler et al. [48]	411 (81)	BT	All	Range 7.5–76.8	84
Davidson et al. [39]	220 (38)	STS	Extremity	M 54.4 (sd 16.6)	59
Dressler et al. [42]	36 (52)	GIST	GI	Range 42–89	56
Edelmann et al. [43]	80 (67)	OS	ns	M 38.9 (sd 7.1)	58
Leiser et al. [62]	83 (91)	Rhabdomyosarcoma	ns	Range 0.8–15.5^3	55
Phukan et al. [77]	33 (73)	BT	Sacrum	Range 23–77^5	58
Poort et al. [79]	89 (75)	GIST	GI	Range 21–86	58
Weiner et al. [103]	21 (91)	BT	ns	Range 9–18	52
Bekkering et al. [108]	20 (45)	BT	Knee	M 22.3 (sd 4.0)	50
Fernandez-Pineda et al. [47]	206 (63)	BT, STS	Extremity	Range 19.4–65.1	52
Podleska et al. [78]	26 (96)	STS	LL	Range 12–73	54
Ranft et al. [81]	614 (47)	ES	All	ns	56
Saebye et al. [87]	128 (67)	STS	LL	IQR 47–70	45
Wong et al. [105]	48^2	STS	Retroperitoneal	Range 38–82^3	54

BT: bone tumour; ES: Ewing sarcoma; GIST: gastrointestinal stromal tumour; IQR: interquartile range; LL: lower limb; M: mean; ns: not stated; OS: osteosarcoma; sd: standard deviation; STS: soft tissue sarcoma. ¹Calculated from interpreting the information reported in the paper not necessarily what the authors report. ²Not enough detail reported to be able to calculate a response rate. ³Age at diagnosis; age at study not reported. ⁴Age reported for each group: diagnosis, treatment, and follow-up. ⁵The age reported in the text is different to the age reported in the table (range 33–77). ⁶Reported for the whole cohort (n = 664) not just the 411 respondents of the patient-reported outcome.